Nanoviricides, Inc. (OTC: NNVC), B+ rating and 9-month price target of $3.00 per share

Ludlow BioVentures Member of the Ludlow Biotech Stock Index - Click Here	Nanoviricides, Inc. OTC: NNVC	Stock Report Launch May 05, 2008 OTC Symbol: NNVC

Sector: Biotechnology Sub-Industry: viral research Fully Reporting: Yes
		Summary: The Company is a development stage company that is creating special purpose nanomaterials for viral therapy.

Price at Research Launch:	$0.69	|	52-Week Range:	$0.29-$1.25

Prepared by: Ludlow Capital Research

Business Summary NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others. www.nanoviricides.com		Quantitative Evaluations Ludlow Capital Rating: B+ D C B- B B+ A- A A+ Volatility: High Low Average High Technical Rating: BULLISH Relative Stock Strength: 65 65 1 Lowest Highest 99
REGISTER FOR UPDATES
Request an Investor Packet on NNVC
INVESTMENT OPINION
Ludlow BioVentures Initiates Research Coverage on Nanoviricides, Inc. (NNVC) Last Updated: May 05, 2008 - 10:18pm EST NEW YORK--May 05, 2008--Ludlow BioVentures initiates research coverage on Nanoviricides, Inc. (OTC: NNVC), a development stage company that is creating special purpose nanomaterials for viral therapy, with a B+ rating and 9-month price target of $3.00 per share. COVERAGE SUMMARY NanoViricieds (NNVC) utilize creative and unique nanomaterials for targeting and destroying viruses. The company's nanoviricide(TM) drug candidates are designed to specifically attack enveloped virus particles and to dismantle them, as opposed to vaccines which work to prevent the delivery of the virus payload. This unique approach makes NNVC a interesting play in the field of viral therapy. NanoViricides is using this unique viral approach for use and potential destruction of such viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others. Due to the company's recent test results with such diseases as Ebola and HIV, and their different approach to viral therapy, Ludlow BioVentures is initiating research coverage on the company with a B+ rating, and a 9-month price target of $3.00 per share. For updates on this research opinion, or additional information on the company register online here. About Ludlow BioVentures, Inc Based in New York City, Ludlow BioVenture is a venture capital and research advisory firm with a specific focus on the biotechnology sector. The goal of the firm is to promote investments into biotech ventures worldwide. Ludlow BioVentures owns and operates the Ludlow BioVenture Index, which tracks a wide basket of US traded large and small cap biotechnology stocks. www.ludlowcapital.com/bioventures/ ------------------------ Contact: Ludlow BioVentures, Inc. Thomas J. Latino JD, PhD Phone: (201)-245-4278 Email: tlatino@ludlowcapital.com

Key Stock Statistics As of March 31, 2008 12 Month P/E NA | Yield NiL Shs. outstanding 119m Shareholders UR Shs. restricted UR Market cap. (M) $101m Avg. daily vol. (K) 101k Inst. holdings 0% Value of $10,000 invested 1 year ago: UR Dividend Data No dividends have been paid on the common stock.

Revenues/Earnings Data Fiscal year ending December 31 Revenues (millions $) 2008 2007 2006 2005 2004 2003 1Q UR UR UR 2Q UR UR UR 3Q UR UR UR 4Q -- UR UR Yr. NA Earnings per Share ($) 2008 2007 2006 2005 2004 2003 1Q UR UR NA 2Q UR UR NA 3Q UR UR NA 4Q -- UR NA Yr. UR UR UR Source: Company Press Release, and filings with SEC.

Legend: E-Estimated. NA-Not Available. NM-Not Meaningful. NR-Not Ranked. UR-Under Review.

Office: 135 Wood Street, # 205 West Haven, CT 06516 Telephone: 203-937-6137 Email: info@nanoviricides.com	Chairman: Dr. Anil R. Diwan Ph.D. CFO: Dr. Eugene Seymour MD, MPH Auditor: Website: www.nanoviricide.com	Founded: UR Domicile: CT Employees: 2 Analyst: Thomas Latino, PhD

Source